ARTBIO Announces $132 Million Series B Financing to Advance Pipeline of Alpha Radioligand Therapies and Expand Manufacturing and Supply Chain Infrastructure
Summary
ARTBIO closed a $132 million Series B financing led by Sofinnova Investments and B Capital, with support from several existing and new investors. The company will use the capital to advance its lead alpha radioligand therapy AB001 through Phase II trials and move additional programs toward IND readiness. ARTBIO will also expand its manufacturing and supply chain infrastructure to support global clinical trials and future commercialization. The company says its proprietary isotope isolation and generator technology helps enable distributed production of clinical-grade lead-212.
Funding
Amount
$132.0M
Total raised
Date
July 29, 2025
Announcement date
Investors
F-Prime Capital, Alexandria Venture Investments, Omega Fund Management, Qatar Investment Authority, Third Rock Ventures
Lead investors
Company
artbio.com
Funded company
Classifications
industries
No industries detected
applications
No applications detected
AskAI Classifications
Labels
No AI classifications detected